![\"\"](\"https:\/\/www.merckvaccines.com\/gardasil9\/wp-content\/uploads\/sites\/159\/2024\/04\/CAT_G9_HumanImgHero_Desktop.webp\")
Millions of men and women aged 45 and under may still benefit from vaccination5,6<\/sup><\/strong><\/h1>Help protect against certain HPV-related cancers caused by HPV types to which they haven\u2019t yet been exposed.<\/p>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n\n\n\n<\/div>\n\n\n\n<\/div>\n\n\n\n\nGARDASIL 9<\/span> helps protect against certain cancers caused by 7 HPV typesa<\/sup><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n- Cervical<\/li>
- Vulvar<\/li>
- Oropharyngeal*<\/li><\/ul><\/div>\n\n\n\n
*Continued approval contingent upon confirmatory trial.<\/p><\/div><\/div>\n<\/div>\n\n\n\n
\n- Vaginal<\/li>
- Anal<\/li><\/ul><\/div>\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\n
a<\/sup>HPV Types 16, 18, 31, 33, 45, 52, and 58. <\/p>\n\n\n\nHPV is not the only cause of these cancers.<\/p>\n\n\n\n
<\/div>\n\n\n\n\n\nHPV-related oropharyngeal cancer has become the most common HPV-related cancer7<\/sup><\/code><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nCDC-estimated 2012-2016<\/strong> US incidence model of cancer cases attributed to 7 HPV types (16, 18, 31, 33, 45, 52, and 58)7<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nFor most people, HPV clears on its own.<\/strong> But for those who don\u2019t clear the virus, it could cause certain cancers and diseases.6, 8, 9<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\n~31,400 HPV-attributable cancer cases per year7<\/sup><\/strong><\/p>\n\n\n\n\n![\"Annual](\"https:\/\/www.merckvaccines.com\/gardasil9\/wp-content\/uploads\/sites\/159\/2025\/04\/Anual_Cancer_Cases_Desktop_1.svg\")
![\"\"](\"https:\/\/www.merckvaccines.com\/gardasil9\/wp-content\/uploads\/sites\/159\/2025\/04\/Anual_Cancer_Cases_Mobile_1.svg\" "\\"\\"")
<\/figure><\/div>\n\n\n\nThe oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.<\/p>\n\n\n\n
<\/div>\n\n\n\nUS Cancer Statistics assessed incidence of HPV-associated cancers to estimate the annual number of cancers caused by HPV, overall, and by state in 2012-2016.7<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nThe estimated number of cancers attributable to HPV was calculated by multiplying the average number of HPV-associated cancers by the percentage of cancers diagnosed from 1993-2005 (prevaccine) that were attributable to HPV.7,10<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nNot all cervical, vulvar, vaginal, anal, and oropharyngeal cancers are caused by HPV.7<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nDetection of HPV DNA in an HPV study is insufficient to indicate a causal relation with the tumor.10<\/sup><\/p>\n<\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\nDon\u2019t assume adults through age 45 have been vaccinated<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n<\/div>\n\n\n\nAccording to National Health Interview Survey (NHIS) data based on a 2019 analysis11,b<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\n![\"\"](\"https:\/\/www.merckvaccines.com\/gardasil9\/wp-content\/uploads\/sites\/159\/2024\/06\/adult_women_info-stat_left_align_v3.svg\")
![\"\"](\"https:\/\/www.merckvaccines.com\/gardasil9\/wp-content\/uploads\/sites\/159\/2024\/05\/info-stat_center_align_2.svg\" "\\"\\"")
<\/figure><\/div>\n\n\n\n<\/div>\n\n\n\nb<\/sup>Note that 718 respondents did not answer the question linked to the outcome of interest (“Have you ever received an HPV shot or vaccine?”) and were therefore excluded from the logistic regression analysis. We built crude and adjusted models, and using multivariable logistic regression, we estimated associations between sociodemographic factors and HPV vaccine uptake, obtaining odds ratios at a 95% confidence interval to determine statistical significance.11<\/sup><\/p>\n\n\n\n
GARDASIL 9<\/span> helps protect against certain cancers caused by 7 HPV typesa<\/sup><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n- Cervical<\/li>
- Vulvar<\/li>
- Oropharyngeal*<\/li><\/ul><\/div>\n\n\n\n
*Continued approval contingent upon confirmatory trial.<\/p><\/div><\/div>\n<\/div>\n\n\n\n
\n- Vaginal<\/li>
- Anal<\/li><\/ul><\/div>\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\n
a<\/sup>HPV Types 16, 18, 31, 33, 45, 52, and 58. <\/p>\n\n\n\nHPV is not the only cause of these cancers.<\/p>\n\n\n\n
<\/div>\n\n\n\n\n\nHPV-related oropharyngeal cancer has become the most common HPV-related cancer7<\/sup><\/code><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nCDC-estimated 2012-2016<\/strong> US incidence model of cancer cases attributed to 7 HPV types (16, 18, 31, 33, 45, 52, and 58)7<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nFor most people, HPV clears on its own.<\/strong> But for those who don\u2019t clear the virus, it could cause certain cancers and diseases.6, 8, 9<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\n~31,400 HPV-attributable cancer cases per year7<\/sup><\/strong><\/p>\n\n\n\n\n<\/figure><\/div>\n\n\n\nThe oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.<\/p>\n\n\n\n
<\/div>\n\n\n\nUS Cancer Statistics assessed incidence of HPV-associated cancers to estimate the annual number of cancers caused by HPV, overall, and by state in 2012-2016.7<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nThe estimated number of cancers attributable to HPV was calculated by multiplying the average number of HPV-associated cancers by the percentage of cancers diagnosed from 1993-2005 (prevaccine) that were attributable to HPV.7,10<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nNot all cervical, vulvar, vaginal, anal, and oropharyngeal cancers are caused by HPV.7<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nDetection of HPV DNA in an HPV study is insufficient to indicate a causal relation with the tumor.10<\/sup><\/p>\n<\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\nDon\u2019t assume adults through age 45 have been vaccinated<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n<\/div>\n\n\n\nAccording to National Health Interview Survey (NHIS) data based on a 2019 analysis11,b<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\n<\/figure><\/div>\n\n\n\n<\/div>\n\n\n\nb<\/sup>Note that 718 respondents did not answer the question linked to the outcome of interest (“Have you ever received an HPV shot or vaccine?”) and were therefore excluded from the logistic regression analysis. We built crude and adjusted models, and using multivariable logistic regression, we estimated associations between sociodemographic factors and HPV vaccine uptake, obtaining odds ratios at a 95% confidence interval to determine statistical significance.11<\/sup><\/p>\n\n\n\n
- Cervical<\/li>
- Vulvar<\/li>
- Oropharyngeal*<\/li><\/ul><\/div>\n\n\n\n
*Continued approval contingent upon confirmatory trial.<\/p><\/div><\/div>\n<\/div>\n\n\n\n
\n- Vaginal<\/li>
- Anal<\/li><\/ul><\/div>\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\n
a<\/sup>HPV Types 16, 18, 31, 33, 45, 52, and 58. <\/p>\n\n\n\n
HPV is not the only cause of these cancers.<\/p>\n\n\n\n
<\/div>\n\n\n\n\n\nHPV-related oropharyngeal cancer has become the most common HPV-related cancer
7<\/sup><\/code><\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nCDC-estimated 2012-2016<\/strong> US incidence model of cancer cases attributed to 7 HPV types (16, 18, 31, 33, 45, 52, and 58)7<\/sup><\/p>\n\n\n\n
<\/div>\n\n\n\nFor most people, HPV clears on its own.<\/strong> But for those who don\u2019t clear the virus, it could cause certain cancers and diseases.6, 8, 9<\/sup><\/p>\n\n\n\n
<\/div>\n\n\n\n~31,400 HPV-attributable cancer cases per year7<\/sup><\/strong><\/p>\n\n\n\n\n
<\/figure><\/div>\n\n\n\nThe oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.<\/p>\n\n\n\n
<\/div>\n\n\n\nUS Cancer Statistics assessed incidence of HPV-associated cancers to estimate the annual number of cancers caused by HPV, overall, and by state in 2012-2016.7<\/sup><\/p>\n\n\n\n
<\/div>\n\n\n\nThe estimated number of cancers attributable to HPV was calculated by multiplying the average number of HPV-associated cancers by the percentage of cancers diagnosed from 1993-2005 (prevaccine) that were attributable to HPV.7,10<\/sup><\/p>\n\n\n\n
<\/div>\n\n\n\nNot all cervical, vulvar, vaginal, anal, and oropharyngeal cancers are caused by HPV.7<\/sup><\/p>\n\n\n\n
<\/div>\n\n\n\nDetection of HPV DNA in an HPV study is insufficient to indicate a causal relation with the tumor.10<\/sup><\/p>\n<\/div><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\nDon\u2019t assume adults through age 45 have been vaccinated<\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n<\/div>\n\n\n\nAccording to National Health Interview Survey (NHIS) data based on a 2019 analysis11,b<\/sup><\/p>\n\n\n\n
<\/div>\n\n\n\n<\/figure><\/div>\n\n\n\n<\/div>\n\n\n\nb<\/sup>Note that 718 respondents did not answer the question linked to the outcome of interest (“Have you ever received an HPV shot or vaccine?”) and were therefore excluded from the logistic regression analysis. We built crude and adjusted models, and using multivariable logistic regression, we estimated associations between sociodemographic factors and HPV vaccine uptake, obtaining odds ratios at a 95% confidence interval to determine statistical significance.11<\/sup><\/p>\n\n\n\n
![\"\"](\"https:\/\/www.merckvaccines.com\/gardasil9\/wp-content\/uploads\/sites\/159\/2024\/06\/women_info-stat_left_align.svg\")
![\"\"](\"https:\/\/www.merckvaccines.com\/gardasil9\/wp-content\/uploads\/sites\/159\/2024\/09\/women_info-stat_center_align_v3.svg\" "\\"\\"")
<\/figure><\/div>\n<\/div>\n\n\n\n![\"\"](\"https:\/\/www.merckvaccines.com\/gardasil9\/wp-content\/uploads\/sites\/159\/2024\/06\/men_info-stat_left_align.svg\")
![\"\"](\"https:\/\/www.merckvaccines.com\/gardasil9\/wp-content\/uploads\/sites\/159\/2024\/09\/men_info-stat_center_align_v4.svg\" "\\"\\"")
<\/figure><\/div>\n<\/div>\n<\/div>\n\n\n\n